AU2018368466B2 - VEGFR-Fc fusion protein formulations - Google Patents

VEGFR-Fc fusion protein formulations Download PDF

Info

Publication number
AU2018368466B2
AU2018368466B2 AU2018368466A AU2018368466A AU2018368466B2 AU 2018368466 B2 AU2018368466 B2 AU 2018368466B2 AU 2018368466 A AU2018368466 A AU 2018368466A AU 2018368466 A AU2018368466 A AU 2018368466A AU 2018368466 B2 AU2018368466 B2 AU 2018368466B2
Authority
AU
Australia
Prior art keywords
formulation
val
ser
thr
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018368466A
Other languages
English (en)
Other versions
AU2018368466A1 (en
Inventor
William J. Callahan
Robert Matthew FESINMEYER
Rahul Rajan KAUSHIK
Sai Chakradhar PADALA
Yael Wexler-Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2018368466A1 publication Critical patent/AU2018368466A1/en
Application granted granted Critical
Publication of AU2018368466B2 publication Critical patent/AU2018368466B2/en
Priority to AU2024205240A priority Critical patent/AU2024205240B2/en
Priority to AU2026203779A priority patent/AU2026203779A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018368466A 2017-11-17 2018-11-16 VEGFR-Fc fusion protein formulations Active AU2018368466B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024205240A AU2024205240B2 (en) 2017-11-17 2024-07-31 VEGFR-Fc fusion protein formulations
AU2026203779A AU2026203779A1 (en) 2017-11-17 2026-05-15 VEGFR-Fc fusion protein formulations

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762587733P 2017-11-17 2017-11-17
US62/587,733 2017-11-17
US201862618904P 2018-01-18 2018-01-18
US62/618,904 2018-01-18
PCT/US2018/061644 WO2019099921A2 (en) 2017-11-17 2018-11-16 Vegfr-fc fusion protein formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205240A Division AU2024205240B2 (en) 2017-11-17 2024-07-31 VEGFR-Fc fusion protein formulations

Publications (2)

Publication Number Publication Date
AU2018368466A1 AU2018368466A1 (en) 2020-06-18
AU2018368466B2 true AU2018368466B2 (en) 2024-06-20

Family

ID=65041879

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018368466A Active AU2018368466B2 (en) 2017-11-17 2018-11-16 VEGFR-Fc fusion protein formulations
AU2024205240A Active AU2024205240B2 (en) 2017-11-17 2024-07-31 VEGFR-Fc fusion protein formulations
AU2026203779A Pending AU2026203779A1 (en) 2017-11-17 2026-05-15 VEGFR-Fc fusion protein formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2024205240A Active AU2024205240B2 (en) 2017-11-17 2024-07-31 VEGFR-Fc fusion protein formulations
AU2026203779A Pending AU2026203779A1 (en) 2017-11-17 2026-05-15 VEGFR-Fc fusion protein formulations

Country Status (8)

Country Link
US (2) US12156900B2 (cg-RX-API-DMAC7.html)
EP (1) EP3709971A2 (cg-RX-API-DMAC7.html)
JP (2) JP7536640B2 (cg-RX-API-DMAC7.html)
AU (3) AU2018368466B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082899A1 (cg-RX-API-DMAC7.html)
MA (1) MA50908A (cg-RX-API-DMAC7.html)
MX (2) MX2020005170A (cg-RX-API-DMAC7.html)
WO (1) WO2019099921A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099921A2 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (ko) * 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
WO2021050687A1 (en) * 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
EP4190310A4 (en) * 2020-07-31 2024-01-17 Celltrion, Inc. Stable pharmaceutical preparation
IL305010A (en) * 2021-02-17 2023-10-01 Arecor Ltd An aqueous preparation of a transgenic protein structure that includes an FC domain
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
US12240888B1 (en) * 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses
WO2025227916A1 (zh) 2024-04-29 2025-11-06 齐鲁制药有限公司 包含阿柏西普和其变体的组合物以及相关方法和应用
JP2026054929A (ja) 2024-09-17 2026-03-30 キオクシア株式会社 メモリシステムおよび制御方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN103816115B (zh) 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
AU2012340107B2 (en) 2011-11-18 2017-06-15 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
WO2013096221A1 (en) 2011-12-21 2013-06-27 Amgen Inc. Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
CN107115294B (zh) 2012-01-19 2019-10-18 北京康弘生物医药有限公司 一种含有vegf拮抗剂的滴眼液
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
JP2015519373A (ja) 2012-06-01 2015-07-09 オプソテック コーポレイションOphthotech Corporation 抗pdgfアプタマーおよびvegf拮抗薬を含む組成物
UA115789C2 (uk) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2014078627A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
MX377714B (es) 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
MX390837B (es) 2015-10-16 2025-03-21 Regeneron Pharma Composiciones de proteinas estables.
MY200764A (en) * 2015-12-16 2024-01-14 Regeneron Pharma Compositions and methods of manufacturing protein microparticles
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2017168296A1 (en) 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
BR112019011900A2 (pt) 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
US20200255496A1 (en) 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
CN107595765A (zh) 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
WO2019099921A2 (en) 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
MY202872A (en) 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
EP3730126B1 (en) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
WO2020055123A1 (ko) 2018-09-10 2020-03-19 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
US20210353713A1 (en) 2018-10-26 2021-11-18 Amgen Inc. Formulations comprising a tris buffer and a protein
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept

Also Published As

Publication number Publication date
AU2024205240A1 (en) 2024-08-22
EP3709971A2 (en) 2020-09-23
JP2024160287A (ja) 2024-11-13
WO2019099921A2 (en) 2019-05-23
JP7536640B2 (ja) 2024-08-20
JP2021503485A (ja) 2021-02-12
MX2020005170A (es) 2020-10-16
US20200338164A1 (en) 2020-10-29
WO2019099921A3 (en) 2019-06-27
CA3082899A1 (en) 2019-05-23
AU2024205240B2 (en) 2026-05-14
MA50908A (fr) 2020-09-23
AU2026203779A1 (en) 2026-06-04
US12156900B2 (en) 2024-12-03
JP7879902B2 (ja) 2026-06-24
US20250082726A1 (en) 2025-03-13
AU2018368466A1 (en) 2020-06-18
MX2025004779A (es) 2025-05-02

Similar Documents

Publication Publication Date Title
AU2024205240B2 (en) VEGFR-Fc fusion protein formulations
US10980884B2 (en) Stable aqueous etanercept composition
US20230025418A1 (en) Vegfr-fc fusion protein formulations
US20240415929A1 (en) Formulations comprising a tris buffer and a protein
US11000588B2 (en) Etanercept formulations stabilized with sodium chloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)